NCT01318980View on ClinicalTrials.gov

A Single Dose Study to Assess the Regional Absorption and Bioavailability of 100mg GSK2190915A

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

March 11, 2011

Study Completion Date

March 11, 2011

Conditions
Asthma
Interventions
DRUG

GSK2190915 100mg milled tablet

Taken orally

DRUG

[14C] radiolabelled GSK2190915 solution

Microtracer solution

DRUG

GSK2190915 100mg milled tablet administered to the proximal small bowel.

Ground half of a 200mg tablet. Administered via Enterion capsule.

DRUG

GSK2190915 100mg milled tablet administered to the distal small bowel.

Ground half of a 200mg tablet. Administered via Enterion capsule.

DRUG

GSK2190915 100mg enteric-coated tablet.

Taken orally

Trial Locations (1)

NG11 6JS

GSK Investigational Site, Nottingham

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01318980 - A Single Dose Study to Assess the Regional Absorption and Bioavailability of 100mg GSK2190915A | Biotech Hunter | Biotech Hunter